학술논문
Neuropathy risk prior to therapy
Document Type
article
Author
Shikuma, CM; Gerschenson, M; Ananworanich, J; Valcour, VG; Teeratakulpisarn, N; Jadwattanakul, T; DeGruttola, V; Liang, C‐Y; McArthur, JC; Ebenezer, GJ; Chomchey, N; Praihirunkit, P; Hongchookiath, P; Mathajittiphun, P; Nakamoto, B; Hauer, P; Phanuphak, P; Phanuphak, N; team, the SEARCH 003 protocol
Source
HIV Medicine. 13(10)
Subject
Language
Abstract
ObjectivesDistal leg epidermal nerve fibre density (ENFD) is a validated predictor of small unmyelinated nerve fibre damage and neuropathy risk in HIV infection. As pre-existing damage may increase the risk of neuropathy following antiretroviral (ARV) therapy, particularly when the regimen contains stavudine (d4T), we assessed the relationship between ENFD and various parameters including mitochondrial factors in HIV-infected Thai individuals naïve to ARV therapy.MethodsDistal leg and proximal thigh ENFDs were quantified in HIV-infected Thai individuals without neuropathy prior to randomization to a HIV clinical trial that focused on mitochondrial toxicity issues. We assessed their association with various clinical and immunovirological parameters as well as with peripheral blood mononuclear cell (PBMC) mitochondrial (mt) DNA copies/cell, oxidative phosphorylation (OXPHOS) complex I (CI) and complex IV (CIV) enzyme activities, and mt 8-oxo-deoxyguanine (8-oxo-dG) break frequencies.ResultsIn 132 subjects, the median (interquartile range) ENFD (fibres/mm) values were 21.0 (16.2-26.6) for the distal leg and 31.7 (26.2-40.0) for the proximal thigh. By linear regression, lower CD4 count (P